Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...
bovnews6d
Vigil Neuroscience Inc (VIGL) Reported a – Operating Margin Last Year—What’s the Real Story?
William Blair has recently initiated Vigil Neuroscience Inc (VIGL) stock to Outperform rating, as announced on December 4, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had ...
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment
Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...
Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
ETF Daily News1mon
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Decreases By 18.4%
abrdn plc purchased a new stake in shares of Vigil Neuroscience in the third quarter valued at $799,000. Ensign Peak Advisors Inc boosted its position in shares of Vigil Neuroscience by 72.8% in ...
Pro-Vigil Earns Great Place To Work Certification™ in U.S.
Pro-Vigil, a provider of AI-enabled remote video monitoring and crime deterrence solutions, today announced it has been Certified™ in the U.S. by Great Place To Work®. This year, 74% of Pro-Vigil ...